IL6 and neoplasm: TAMs were previously shown to activate the JAK2/STAT3 pathway through IL-6, inhibit tumor suppressor miRNAs like R-506-3p and its target FoxQ1, secrete CCL22, and activate the PI3K/AKT pathway (64).